Tuesday, February 20, 2018 10:15 PM ET
Nektar Therapeutics (NKTR) Insiders Make Significant Share Sales
A substantial level of insider sales in Nektar Therapeutics was reported in form 4 documents filed with the SEC today. Six insiders listed below, sold 28,990 shares in the company having a market value of approximately $2,404,431. These are the first insider buy/sell trades in the past 90 days. Adding the most recent activity to this 90-day history indicates insider trades have averaged 4,832 shares per transaction.
Over the last 90 days, the number of insider buy/sell trades at Nektar Therapeutics is above its 191-company peer group average. The Biotechnology & Medical Research peer group saw 151 buy/sell trades during this period for an average of 0.8 transactions per company. However, the number of shares traded per transaction by Nektar Therapeutics insiders is lower than its peers. Within the peer group there were 11,494,769 shares purchased and 12,429,588 shares sold with company insiders having sold 6,191 shares on average over this time period.
The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Today’s Insider Activity
* Howard W Robin, Director and Officer, sold 12,788 shares
* Gil M Labrucherie, Officer, sold 3,477 shares
* John Nicholson, Officer, sold 4,879 shares
* Jillian B Thomsen, Officer, sold 2,545 shares
* Dr Maninder Hora, Officer, sold 2,875 shares
* Dr Stephen K Doberstein, Officer, sold 2,426 shares
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.